Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the biotechnology and medical research peer group is "buy".
- Wall Street's median 12-month price target for Palvella Therapeutics Inc is $225.00, about 59.8% above its August 3 closing price of $140.78.
Quarterly results
- Palvella Therapeutics said its second-quarter net loss widened year over year amid higher research and development and general and administrative expenses.
- Cash and short-term investments totaled $250.6 million as of June 30, 2026.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Loss Per Share | | $1.52 | |
| Q2 Net Loss | | $21.87 million | |
What drove expenses higher
PVLA•
